`Exhibit W
`
`Genome Exhibit 1061
`Page 1 of 6
`
`Genome Exhibit 1061
`Page 1 of 6
`
`
`
`5/13/2019
`
`Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found... | Esmo Open
`
`Weuse cookies to improve our service and to tailor our content and advertising to you. More info
`
`
`BARCELONA EMv0nS)
`ESMDpen itn
`
`;
`
`
`
`
`Register now!
`
`:aia
`
`4
`
`Q =
`
`Home-Archive_Volume 2, Issue 1
`
`Article info
`
`Editorial
`
`1506
`
`Article menu
`
`Immune checkpointinhibitors in lung cancer: the holy grail
`has not yet been found... 3
`
`Checkfor
`updates
`
`Authors
`Satheesh Thungappa
`Phase| Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem,Belgium
`PubMedarticles
`Google scholar articles
`
`Jose Ferri
`Phase| Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem,Belgium
`Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain
`PubMedarticles
`Google scholar articles
`
`Christian Caglevic
`Early Development Drugs Unit, Medical Oncology Department,Instituto Oncolégico Fundaci6n Arturo Lopez Péréz,
`Santiago, Chile
`PubMedarticles
`
`Google scholar articles
`
`Francesco Passiglia
`Phase| Early Clinical Trials Unit, Department of Oncology, Universitair Ziekenhuis Antwerpen, Edegem, Belgium
`Departmentof Oncology, Universita degli Studi di Palermo, Palermo,Sicilia,Italy
`PubMedarticles
`Google scholar articles
`
`+
`
`
`Full Text
`
`Help
`
`Luis Raez
`
`Thoracic Oncology Program, Memorial CancerInstitute, Memorial Health Care System, PembrokePines,Florida, USA
`PubMedarticles
`Google scholar articles
`
`https://esmoopen.bmj.com/content/2/1/e000162.info
`
`Genome Exhibit 1061
`Page 2 of 6
`
`1/5
`
`Genome Exhibit 1061
`Page 2 of 6
`
`
`
`
`
`5/13/2019
`
`Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found... | Esmo Open
`
`bmjcareers
`
`Consultant Clinical Oncologist — Breast/Sarcoma
`Lothian
`£80653.00 to £107170.00
`
`Due to the scale of this expansion, a numberof new posts will be advertised over the coming months
`Recruiter: NHS Lothian
`
`Apply for this job
`
`Consultant Clinical Oncologist
`Lothian
`£80653.00 to £107170.00
`
`Due to the scale of this expansion, a numberof new postswill be advertised over the coming months
`Recruiter: NHS Lothian
`
`Apply for this job
`
`Consultant Post in Clinical Oncology(10 sessions) Head & Neck + Upper GI/Urology
`Dundee, Dundee City
`£80,653 - £107,170
`
`An excellent opportunity has arisen to work in Tayside Cancer Centre.
`
`Recruiter: NHS Tayside
`
`Applyfor this job
`
`Consultant Medical Oncologists for Sarcoma
`London(Central), London (Greater)
`£77,913 to £105,042 pa
`
`Youwill join an experienced team of medical, clinical and paediatric oncologists
`Recruiter: University College London Hospitals NHS Foundation Trust A a tk
`
`Other content recommendedfor you
`
`ESMO Copenhagen 2016: a lung cancer‘grand cru’
`Jean-Yves Douillard et al., ESMO open, 2017
`
`Full Text
`
`Help=
`
`Is smoking history the truly best biomarker for immune checkpointinhibitor treatment in advanced
`non-small cell lung cancer?
`Robert Pirker, ESMO open, 2018
`
`30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledgetoaclinical
`practice algorithm: results from an international expert panel meeting of the Italian Association of
`Thoracic Oncology (AIOT)
`Filippo de Marinis et al., ESMO open, 2018
`
`Targeting immune checkpoints in breast cancer: an updateof early results
`Cinzia Solinas et al., ESMO open, 2017
`
`Nivolumab for NSCLC in Japanesepatients: similar benefits, but beware of pneumonitis
`Genome Exhibit 1061
`Page 4 of 6
`
`https://esmoopen.bmj.com/content/2/1/e000162.info
`)
`
`3/5
`
`Genome Exhibit 1061
`Page 4 of 6
`
`
`
`5/13/2019
`
`Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found... | Esmo Open
`
`Johan Vansteenkiste, ESMO open, 2017
`
`Into the Clinic With Nivolumab and Pembrolizumab.
`
`Catherine A Shu etal., Oncologist, 2016
`
`Immunotherapy: Promising results in first and secondline treatment of metastatic bladder cancer
`
`MedicalXpress
`
`4
`
`MEDICALONCOLOGY
` GOOD SCIENCE
`BETTER MEDICINE
`SMO
`
`
`
`
`
`BEST PRACTICE
`
`ute
`Ree
`
`SMO
`
`fenaanmmata
`
`CONTENT
`
`Latest content
`
`Archive
`
`Most read articles
`
`Responses
`
`JOURNAL
`
`About
`
`Editorial policies
`
`Editorial board
`
`Thank you to our reviewers
`
`Sign up for email alerts
`
`AUTHORS
`
`Instructions for authors
`
`Full Text
`
`Help
`
`https://esmoopen.bmj.com/content/2/1/e000162.info
`)
`
`Genome Exhibit 1061
`Page 5 of 6
`
`AIS
`
`Genome Exhibit 1061
`Page 5 of 6
`
`
`
`5/13/2019
`
`Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found... | Esmo Open
`
`Submit an article
`
`FAQs
`
`Open Accessat BMJ
`
`BM) Author Hub
`
`HELP
`
`Contact us
`
`Reprints
`
`Permissions
`
`Advertising
`
`Feedback form
`
`\ ¥ - ut
`
`BM}
`
`Website Terms & Conditions
`
`Privacy & Cookies
`
`Contact BM)
`
`Online: ISSN 2059-7029
`
`Copyright © 2018 European Society for Medical Oncology
`
`IRICP#&150420405-3
`
`Learn more today >
`
`Journal of
`Medical Genetics
`BM)
`
`Keep up to date with the lates:
`advancesin genetic medicine
`
`https://esmoopen.bmj.com/content/2/1/e000162.info
`)
`
`Genome Exhibit 1061
`Page 6 of 6
`
`5/5
`
`Genome Exhibit 1061
`Page 6 of 6
`
`